Fig. 1 · Structure

Documents & Downloads

VTX-2337

Cat. No. A12841 CAS 926927-61-9

TLR8 agonist

VTX-2337 is a small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities.

In Stock

Publications for VTX-2337

1 publication citing this product

  1. Yinwen Cheng, .et al. , Sci Rep, 2021, Jan 15;11(1):1535 PMID: 33452311

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

VTX-2337, studied as a TLR8 agonist, induced IL-1β and IL-18 release in wild-type THP-1 cells. This response was absent in NLRP3-defective cells, supporting a requirement for NLRP3 in this cellular cytokine response. These experiments do not establish direct NLRP3 binding. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
TLR8 EC50 100 nM

VTX-2337 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of VTX-2337 from 3 published references. In vitro models include PBMCs isolated from healthy donor blood.

VTX-2337 In Vitro Studies

In human PBMCs from healthy donors, VTX-2337 stimulated IFNγ, TNFα and IL-1β secretion after 24 h exposure at 0.1–2 μM. These are cellular treatment concentrations, not EC50 values. [2]

Pretreating human PBMCs with VTX-2337 enhanced cetuximab-mediated lysis of UM-22B cancer cells. In the same study, pretreating purified NK cells at 250 nM did not significantly enhance lysis. NK depletion and CD16 blockade supported an NK-dependent, antibody-dependent effect under the tested conditions. [3]

NLRP3-dependent cytokine release in THP-1 cells

Cell-based study · Wild-type THP-1 versus NLRP3-defective THP-1 cells; TPA-differentiated cultures [1]

VTX-2337 induced concentration-related IL-1β and IL-18 release in wild-type cells; the response was absent in NLRP3-defective cells. This supports a cellular NLRP3 requirement, rather than demonstrating direct binding to NLRP3 or receptor selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Secreted IL-1β and IL-18qualitative response Concentration-related secretion in wild type; response absent in NLRP3-defective cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.03–25 μM, as specified for Fig 2E–F
Exposure duration
Overnight
Method
VTX-2337 stimulation of wild-type and NLRP3-defective THP-1 cultures
Reported limits
Vehicle and salt/form not specified. Shared methods give 3 nM–10 μM for the general IL-1β assay; the adopted E–F range is explicitly supplied in the figure caption.
Methods and source locations

Compound reported in the paper: VTX-2337; Compound label in the paper: VTX-2337

Research findings for the named VTX-2337 material in the stated models; no lot validation or salt equivalence.

Fig 2E–F and caption; Results, NLRP3 inflammasome activation; Methods, Analysis of IL-1β secretion and caspase-1 activation in THP-1 cells; Reagents

Secreted IL-1β and IL-18: ELISA; plotted mean ± SEM from triplicate wells; representative of three independent experiments — Fig 2E–F, image/caption and corresponding Results

Cytokine secretion by human PBMCs

Cell-based study · PBMCs isolated from healthy donor blood [2]

VTX-2337 stimulated IFNγ, TNFα and IL-1β secretion after 24 h. Concentrations are treatment exposures; no potency estimate is derived.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IFNγ, TNFα and IL-1β in culture mediumqualitative response Increased secretion with VTX-2337 relative to the 0 μM condition[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.1–2 μM; 0 μM comparison
Exposure duration
24 h
Method
Exposure of isolated human PBMCs to VTX-2337
Reported limits
Vehicle, salt/form and donor/independent-experiment count for panels A–C are not specified in the read methods/caption; n=3 is explicitly attached to G–I and is not transferred here.
Methods and source locations

Compound reported in the paper: VTX-2337; Compound label in the paper: VTX-2337

Research findings for the named VTX-2337 material in the stated models; no lot validation or salt equivalence.

Fig 3A–C and caption; Results, VTX-2337 induces immune cell activation; Methods, In vitro immune cell activation; Cell lines and reagents

IFNγ, TNFα and IL-1β in culture medium: ELISA; no exact curve values inferred — Fig 3A–C, image/caption and corresponding Results

PBMC-dependent enhancement of cetuximab-mediated cytotoxicity

Cell-based study · Human PBMCs and purified NK cells tested against UM-22B head-and-neck cancer targets [3]

PBMC pretreatment enhanced cetuximab-mediated lysis. Pretreatment of purified NK cells did not significantly enhance lysis under these conditions (reported p=0.13). NK depletion after PBMC pretreatment abolished cytotoxicity, while post-treatment-isolated NK cells retained activity. CD16 blockade abolished NK-cell ADCC.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Specific target-cell lysisqualitative response Enhanced cetuximab-mediated lysis after PBMC pretreatment; no significant enhancement after direct purified-NK pretreatment (p=0.13); loss of activity after NK depletion[3]

Literature-Reported Treatment Conditions

Treatment concentration
VTX-2337 250 nM; cetuximab or control IgG1 10 μg/mL
Exposure duration
18 h pretreatment, then 4 h cytotoxicity assay
Method
Effector pretreatment followed by 51Cr-release assay; PBMC E:T 50:1, purified NK E:T 10:1 (panel b), post-treatment-isolated NK E:T 2.5:1 (panel c)
Vehicle
Medium control; compound solvent not specified
Co-treatment
Cetuximab; matched IgG1 controls; CD16-blocking 3G8 and NK-depleted effector controls
Reported limits
Salt/form and the independent donor count for panels 1a–c are not explicitly stated in the read caption. Patient panel 1d and the 40-donor genotype design are not adopted.
Methods and source locations

Compound reported in the paper: VTX-2337; Compound label in the paper: VTX-2337

Research findings for the named VTX-2337 material in the stated models; no lot validation or salt equivalence.

Fig 1a–c, image/caption; Results, VTX-2337 enhances cetuximab-mediated cellular cytotoxicity; Methods, Cellular components, Cytotoxicity assays and Statistical analysis

Specific target-cell lysis: 51Cr release; spontaneous and maximum-release controls defined in Methods — Fig 1a–c, image/caption; Results paragraphs on purified and depleted NK cells

VTX-2337 In Vivo Studies

In male cynomolgus monkeys, a single subcutaneous 10 mg/kg dose of VTX-2337 increased circulating IL-18; the reported level at 6 h was 68.7 ± 4.4 pg/mL (mean ± SEM; n=6 per dose group). This pharmacodynamic experiment assessed cytokine induction rather than antitumor efficacy. [1]

IL-18 pharmacodynamics in cynomolgus monkeys

Animal study · Male cynomolgus monkeys, 2.9–4.9 kg; n=6 per dose group [1]

A single 10 mg/kg subcutaneous dose increased circulating IL-18. The reported 6 h value was 68.7 ± 4.4 pg/mL (mean ± SEM). This is a systemic cytokine response, not evidence of tumor control or direct in vivo NLRP3 causality.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma IL-18 at 6 h after 10 mg/kgplasma concentration 68.7 ± 4.4 pg/mL (mean ± SEM; n=6 in dose group)[1]

Conditions shared by the study groups

Route
Subcutaneous bolus, intrascapular area
Frequency
Single administration
Treatment course
Plasma sampled predose and 6, 12, 24 and 96 h after dosing
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
VTX-2337, 10 mg/kg
10 mg/kg
Predose within the treated group; a 1 mg/kg group was also studied, without a separate untreated group describedIL-18 increased after dosing; reported 6 h mean 68.7 ± 4.4 pg/mL (mean ± SEM).[1]
VTX-2337, 10 mg/kg
Model: Male cynomolgus monkeys; n=6 per dose group
Reported limits: Vehicle and salt/form not specified. No tumor efficacy endpoint. IL-1β numerical results are excluded because Results use ng/mL while the figure axis and caption use pg/mL.
Methods and source locations

Compound reported in the paper: VTX-2337; Compound label in the paper: VTX-2337

Research findings for the named VTX-2337 material in the stated models; no lot validation or salt equivalence.

Fig 6B and caption (image viewed); Results, In vivo administration of VTX-2337 in cynomolgus monkeys induces circulating IL-1β and IL-18; corresponding Methods; Statistical analysis

Plasma IL-18 at 6 h after 10 mg/kg: Human MAP v1.6 inflammation panel; mean ± SEM specified by figure caption — Fig 6B image/caption; corresponding Results paragraph; monkey administration Methods

VTX-2337, 10 mg/kg · Fig 6B and caption (image viewed); Results, In vivo administration of VTX-2337 in cynomolgus monkeys induces circulating IL-1β and IL-18; corresponding Methods; Statistical analysis

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 926927-61-9
Applications TLR8 agonist
Formula C28H34N4O2
Molecular Weight 458.6
SMILES
CCCN(CCC)C(=O)C1=CC2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4)N=C(C1)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 48 mg/mL (104.67 mM)
Water Insoluble
Ethanol 13 mg/mL (28.34 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

VTX-2337 Research References

  1. [1] Gregory N Dietsch, Hailing Lu, Yi Yang, et al. Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity PLoS ONE (2016). PMID: 26928328 DOI: 10.1371/journal.pone.0148764 Source material
  2. [2] Yinwen Cheng, Nicholas Borcherding, Ayomide Ogunsakin, et al. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent Scientific Reports (2021). PMID: 33452311 DOI: 10.1038/s41598-020-80957-z Source material
  3. [3] Ryan M Stephenson, Chwee Ming Lim, Maura Matthews, et al. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells Cancer Immunology, Immunotherapy : CII (2013). PMID: 23685782 DOI: 10.1007/s00262-013-1437-3 Source material

Publications

1 publication citing this product

  1. Yinwen Cheng, .et al. , Sci Rep, 2021, Jan 15;11(1):1535 PMID: 33452311

Added to your cart

View Cart Checkout
Loading...